NSTL国家科技图书文献中心

1. Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML) NSTL国家科技图书文献中心

Lagana, Alessandro | Scalzulli, Emilia ... - 《Expert review of hematology》 - 2025,18(1) - 65～79 - 共15页

摘要： pathogenesis was successfully unraveled, with tyrosine kinase | inhibitors (TKIs) representing one of the first-targeted | Introduction: Chronic myeloid leukemia (CML | ) represents one of the first neoplasms whose molecular | therapies. TKIs have revolutionized long-term outcomes of

关键词： Chronic myeloid leukemia | tyrosine kinase inhibitors | TKI resistance | BCR::ABL1 mutations | asciminib | ponatinib | allogeneic hematopoietic stem cell transplant | allo-HSCT

2. Head-to-head comparison of tyrosine kinase inhibitors in renal cell carcinoma using patient-derived cell culture NSTL国家科技图书文献中心

Urquhart, Aaron J. | Glass, Christian H.... - 《Personalized medicine》 - 2025,22(2) - 83～91 - 共9页

摘要： immunotherapy and tyrosine* kinase inhibitors (TKIs). Patient* | Background Metastatic renal cell carcinoma | (RCC) is often treated with a combination of | -derived RCC cells were cultured and inter-individual | differences to treatment with a panel of TKIs were evaluated

关键词： Renal cell carcinoma | patient-derived cell culture | tyrosine kinase inhibitors | sunitinib | cabozantinib | pazopanib | axitinib

3. PD-1 inhibitors improve the efficacy of tyrosine kinase inhibitors combined with transcatheter arterial chemoembolization in advanced hepatocellular carcinoma: a meta-analysis and trial sequential analysis NSTL国家科技图书文献中心

Jiahui Yu | Yong Li ... - 《Scandinavian journal of gastroenterology.》 - 2025,60(5) - 472～484 - 共13页

摘要： and safety of triple therapy with tyrosine kinase | inhibitors (TKIs) combined with transcatheter arterial | chemoembolization (TACE) plus programmed death 1 (PD-1) inhibitors | inhibitors in uHCC was searched using the Embase, PubMed | Background: This meta-analysis and trial

关键词： PD-1 inhibitors; Tyrosine kinase inhibitors; hepatocellular carcinoma; meta-analysis

4. Locally advanced/metastatic non-small-cell lung cancer in Lebanon: focus on ALK tyrosine kinase inhibitors NSTL国家科技图书文献中心

Tfayli, Arafat | Ghanem, Hady ... - 《Future oncology》 - 2025,21(1/2) - 127～137 - 共11页

摘要：-tyrosine* kinase inhibitors (ALK-TKIs) have improved* | Treatment of non-small-cell lung cancers | (NSCLC) has evolved over the last decade. According to | studies, the use of targeted therapies has significantly | increased the life expectancy of patients. Moreover, ALK

关键词： ALK-rearrangement | ALK-tyrosine kinase inhibitor | expert opinion | lung cancer | non-small-cell lung cancer

5. Efficacy and Safety of Tyrosine Kinase Inhibitors in Downstaging and Palliation in Patients with Advanced Differentiated Thyroid Cancer - A Multicentre study NSTL国家科技图书文献中心

Bhat, Ganesh | Chanthar, Vishvak K....... - 《Indian journal of surgical oncology》 - 2025,16(1) - 165～171 - 共7页

摘要： challenging, prompting the exploration of tyrosine kinase | inhibitors (TKIs) to downstage the disease burden before | Thyroid cancer (TC) is the most common | endocrine malignancy worldwide, with differentiated | thyroid cancer (DTC) comprising the majority of cases

关键词： Sorafenib | Lenvatinib | Efficacy and safety of Tyrosine kinase inhibitors | Radioactive refractory differentiated thyroid cancer | Inoperable differentiated thyroid cancer

6. Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases NSTL国家科技图书文献中心

Yamamichi, Gaku | Kato, Taigo ... - 《Anticancer Research》 - 2025,45(2) - 639～650 - 共12页

摘要： options, such as nivolumab or tyrosine kinase inhibitors | immune checkpoint inhibitors* has become the standard* | Background/Aim: Combination therapy with | firstline treatment for metastatic renal cell carcinoma | (mRCC), leading to changes in second-line treatment

关键词： Key Words: Renal cell carcinoma | bone metastasis | second-line | treatment | nivolumab | tyrosine kinase inhibitor | overall survival.

7. Effect on neutrophil migration and antimicrobial functions by the Bruton's tyrosine kinase inhibitors tolebrutinib, evobrutinib, and fenebrutinib NSTL国家科技图书文献中心

De Bondt, Mirre | Renders, Janne ... - 《Journal of Leukocyte Biology》 - 2025,117(3) - qiae160～qiae160 - 共18页

摘要： these are the inhibitors of Bruton's tyrosine kinase | BTK inhibitors* on neutrophil functions. Although* | overlooked in MS. In this study, we used 3 BTK inhibitors | inhibitors prolonged neutrophil survival in an inflammatory | environment. Finally, treatment with BTK inhibitors

关键词： autoimmunity | Bruton's tyrosine kinase signaling | innate immunity | pharmacological inhibitors

8. Catalytic Lysine745 targeting strategy in fourth-generation EGFR tyrosine kinase inhibitors to address C797S mutation resistance NSTL国家科技图书文献中心

Patil, Bhatu R. | Patel, Harun M. - 《European Journal of Medicinal Chemistry》 - 2025,283 - 117140～117140 - 共29页

摘要： tyrosine kinase inhibitors (TKIs) such as Osimertinib | inhibitors that specifically target the catalytic Lys745 | Osimertinib. Both covalent and non-covalent inhibitors | ) for optimizing Lys745-targeting inhibitors. The | Overcoming resistance to third-generation

关键词： Catalytic Lys745 | Non-small cell lung cancer | Osimertinib | C797S | Brigatinib

9. The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction NSTL国家科技图书文献中心

Metsemakers, Sanne J... | Hermens, Rosella P. ...... - 《Value in health》 - 2025,28(2) - 224～232 - 共9页

摘要：-effectiveness of lifelong-prescribed expensive tyrosine kinase | inhibitors (TKIs) for CML is crucial. Prior cost | Objectives: The management of chronic myeloid | leukemia (CML) now includes dose reduction (DR) and | treatment-free remission (TFR). Evaluating the cost

关键词： chronic myeloid leukemia | dose reduction | economic evaluation | healthcare costs | treatment-free remission | tyrosine kinase inhibitors | quality of life

10. Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors NSTL国家科技图书文献中心

Kondo, Takeshi | Matsuki, Eri ... - 《Cancer.》 - 2025,131(1) - e35611～e35611 - 共12页

摘要： pregnant due to the teratogenicity of tyrosine kinase | inhibitors (TKIs). Methods: The authors conducted a | Background: Young female patients with chronic | myeloid leukemia (CML) often face challenges becoming | nationwide survey of female patients with CML who

摘要： pathogenesis was successfully unraveled, with tyrosine kinase | inhibitors (TKIs) representing one of the first-targeted | Introduction: Chronic myeloid leukemia (CML | ) represents one of the first neoplasms whose molecular | therapies. TKIs have revolutionized long-term outcomes of

关键词： Chronic myeloid leukemia | tyrosine kinase inhibitors | TKI resistance | BCR::ABL1 mutations | asciminib | ponatinib | allogeneic hematopoietic stem cell transplant | allo-HSCT

摘要： immunotherapy and tyrosine* kinase inhibitors (TKIs). Patient* | Background Metastatic renal cell carcinoma | (RCC) is often treated with a combination of | -derived RCC cells were cultured and inter-individual | differences to treatment with a panel of TKIs were evaluated

关键词： Renal cell carcinoma | patient-derived cell culture | tyrosine kinase inhibitors | sunitinib | cabozantinib | pazopanib | axitinib

摘要： and safety of triple therapy with tyrosine kinase | inhibitors (TKIs) combined with transcatheter arterial | chemoembolization (TACE) plus programmed death 1 (PD-1) inhibitors | inhibitors in uHCC was searched using the Embase, PubMed | Background: This meta-analysis and trial

关键词： PD-1 inhibitors; Tyrosine kinase inhibitors; hepatocellular carcinoma; meta-analysis

摘要：-tyrosine* kinase inhibitors (ALK-TKIs) have improved* | Treatment of non-small-cell lung cancers | (NSCLC) has evolved over the last decade. According to | studies, the use of targeted therapies has significantly | increased the life expectancy of patients. Moreover, ALK

关键词： ALK-rearrangement | ALK-tyrosine kinase inhibitor | expert opinion | lung cancer | non-small-cell lung cancer

摘要： challenging, prompting the exploration of tyrosine kinase | inhibitors (TKIs) to downstage the disease burden before | Thyroid cancer (TC) is the most common | endocrine malignancy worldwide, with differentiated | thyroid cancer (DTC) comprising the majority of cases

关键词： Sorafenib | Lenvatinib | Efficacy and safety of Tyrosine kinase inhibitors | Radioactive refractory differentiated thyroid cancer | Inoperable differentiated thyroid cancer

摘要： options, such as nivolumab or tyrosine kinase inhibitors | immune checkpoint inhibitors* has become the standard* | Background/Aim: Combination therapy with | firstline treatment for metastatic renal cell carcinoma | (mRCC), leading to changes in second-line treatment

关键词： Key Words: Renal cell carcinoma | bone metastasis | second-line | treatment | nivolumab | tyrosine kinase inhibitor | overall survival.

摘要： these are the inhibitors of Bruton's tyrosine kinase | BTK inhibitors* on neutrophil functions. Although* | overlooked in MS. In this study, we used 3 BTK inhibitors | inhibitors prolonged neutrophil survival in an inflammatory | environment. Finally, treatment with BTK inhibitors

关键词： autoimmunity | Bruton's tyrosine kinase signaling | innate immunity | pharmacological inhibitors

摘要： tyrosine kinase inhibitors (TKIs) such as Osimertinib | inhibitors that specifically target the catalytic Lys745 | Osimertinib. Both covalent and non-covalent inhibitors | ) for optimizing Lys745-targeting inhibitors. The | Overcoming resistance to third-generation

关键词： Catalytic Lys745 | Non-small cell lung cancer | Osimertinib | C797S | Brigatinib

摘要：-effectiveness of lifelong-prescribed expensive tyrosine kinase | inhibitors (TKIs) for CML is crucial. Prior cost | Objectives: The management of chronic myeloid | leukemia (CML) now includes dose reduction (DR) and | treatment-free remission (TFR). Evaluating the cost

关键词： chronic myeloid leukemia | dose reduction | economic evaluation | healthcare costs | treatment-free remission | tyrosine kinase inhibitors | quality of life

摘要： pregnant due to the teratogenicity of tyrosine kinase | inhibitors (TKIs). Methods: The authors conducted a | Background: Young female patients with chronic | myeloid leukemia (CML) often face challenges becoming | nationwide survey of female patients with CML who

关键词： chronic myeloid leukemia | interferon-alpha | pregnancy | treatment discontinuation | treatment-free remission | tyrosine kinase inhibitor

4008-161-200 800-990-8900

国家科技图书文献中心

摘要： pathogenesis was successfully unraveled, with tyrosine kinase | inhibitors (TKIs) representing one of the first-targeted | Introduction: Chronic myeloid leukemia (CML | ) represents one of the first neoplasms whose molecular | therapies. TKIs have revolutionized long-term outcomes of

关键词： Chronic myeloid leukemia | tyrosine kinase inhibitors | TKI resistance | BCR::ABL1 mutations | asciminib | ponatinib | allogeneic hematopoietic stem cell transplant | allo-HSCT

摘要： immunotherapy and tyrosine kinase inhibitors (TKIs). Patient | Background Metastatic renal cell carcinoma | (RCC) is often treated with a combination of | -derived RCC cells were cultured and inter-individual | differences to treatment with a panel of TKIs were evaluated

关键词： Renal cell carcinoma | patient-derived cell culture | tyrosine kinase inhibitors | sunitinib | cabozantinib | pazopanib | axitinib

摘要： and safety of triple therapy with tyrosine kinase | inhibitors (TKIs) combined with transcatheter arterial | chemoembolization (TACE) plus programmed death 1 (PD-1) inhibitors | inhibitors in uHCC was searched using the Embase, PubMed | Background: This meta-analysis and trial

关键词： PD-1 inhibitors; Tyrosine kinase inhibitors; hepatocellular carcinoma; meta-analysis

摘要：-tyrosine kinase inhibitors (ALK-TKIs) have improved | Treatment of non-small-cell lung cancers | (NSCLC) has evolved over the last decade. According to | studies, the use of targeted therapies has significantly | increased the life expectancy of patients. Moreover, ALK

关键词： ALK-rearrangement | ALK-tyrosine kinase inhibitor | expert opinion | lung cancer | non-small-cell lung cancer

摘要： challenging, prompting the exploration of tyrosine kinase | inhibitors (TKIs) to downstage the disease burden before | Thyroid cancer (TC) is the most common | endocrine malignancy worldwide, with differentiated | thyroid cancer (DTC) comprising the majority of cases

关键词： Sorafenib | Lenvatinib | Efficacy and safety of Tyrosine kinase inhibitors | Radioactive refractory differentiated thyroid cancer | Inoperable differentiated thyroid cancer

摘要： options, such as nivolumab or tyrosine kinase inhibitors | immune checkpoint inhibitors has become the standard | Background/Aim: Combination therapy with | firstline treatment for metastatic renal cell carcinoma | (mRCC), leading to changes in second-line treatment

关键词： Key Words: Renal cell carcinoma | bone metastasis | second-line | treatment | nivolumab | tyrosine kinase inhibitor | overall survival.

摘要： these are the inhibitors of Bruton's tyrosine kinase | BTK inhibitors on neutrophil functions. Although | overlooked in MS. In this study, we used 3 BTK inhibitors | inhibitors prolonged neutrophil survival in an inflammatory | environment. Finally, treatment with BTK inhibitors

关键词： autoimmunity | Bruton's tyrosine kinase signaling | innate immunity | pharmacological inhibitors

摘要： tyrosine kinase inhibitors (TKIs) such as Osimertinib | inhibitors that specifically target the catalytic Lys745 | Osimertinib. Both covalent and non-covalent inhibitors | ) for optimizing Lys745-targeting inhibitors. The | Overcoming resistance to third-generation

关键词： Catalytic Lys745 | Non-small cell lung cancer | Osimertinib | C797S | Brigatinib

摘要：-effectiveness of lifelong-prescribed expensive tyrosine kinase | inhibitors (TKIs) for CML is crucial. Prior cost | Objectives: The management of chronic myeloid | leukemia (CML) now includes dose reduction (DR) and | treatment-free remission (TFR). Evaluating the cost

关键词： chronic myeloid leukemia | dose reduction | economic evaluation | healthcare costs | treatment-free remission | tyrosine kinase inhibitors | quality of life

摘要： pregnant due to the teratogenicity of tyrosine kinase | inhibitors (TKIs). Methods: The authors conducted a | Background: Young female patients with chronic | myeloid leukemia (CML) often face challenges becoming | nationwide survey of female patients with CML who

关键词： chronic myeloid leukemia | interferon-alpha | pregnancy | treatment discontinuation | treatment-free remission | tyrosine kinase inhibitor

4008-161-200 800-990-8900

国家科技图书文献中心

摘要： immunotherapy and tyrosine* kinase inhibitors (TKIs). Patient* | Background Metastatic renal cell carcinoma | (RCC) is often treated with a combination of | -derived RCC cells were cultured and inter-individual | differences to treatment with a panel of TKIs were evaluated

摘要：-tyrosine* kinase inhibitors (ALK-TKIs) have improved* | Treatment of non-small-cell lung cancers | (NSCLC) has evolved over the last decade. According to | studies, the use of targeted therapies has significantly | increased the life expectancy of patients. Moreover, ALK

摘要： options, such as nivolumab or tyrosine kinase inhibitors | immune checkpoint inhibitors* has become the standard* | Background/Aim: Combination therapy with | firstline treatment for metastatic renal cell carcinoma | (mRCC), leading to changes in second-line treatment

摘要： these are the inhibitors of Bruton's tyrosine kinase | BTK inhibitors* on neutrophil functions. Although* | overlooked in MS. In this study, we used 3 BTK inhibitors | inhibitors prolonged neutrophil survival in an inflammatory | environment. Finally, treatment with BTK inhibitors